Patents by Inventor Nicolas Baurin

Nicolas Baurin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210189011
    Abstract: The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.
    Type: Application
    Filed: December 28, 2020
    Publication date: June 24, 2021
    Inventors: Nicolas Baurin, Christian Beil, Carsten Corvey, Christian Lange, Danxi Li, Vincent Mikol, Anke Steinmetz, Ercole Rao
  • Publication number: 20200115441
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Application
    Filed: September 24, 2019
    Publication date: April 16, 2020
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • Publication number: 20190359729
    Abstract: The invention provides antibodies that specifically bind to Plasminogen Activator inhibitor type-1 (PAI-1). The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAT-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAT-1 in the active conformational state.
    Type: Application
    Filed: August 6, 2019
    Publication date: November 28, 2019
    Inventors: Alla Pritsker, Patrick Grailhe, Alexey Rak, Magali Mathieu, Christopher Ryan Morgan, Nicolas Baurin, Bruno Poirier, Cyril Daveu, Francis Duffieux, Han Li, Dorothea Kominos, Philip Janiak
  • Patent number: 10465002
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: November 5, 2019
    Assignee: SANOFI
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • Publication number: 20190119365
    Abstract: Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide are provided. Methods of using antibodies specific to the protofibrillar form of the beta-amyloid peptide in the field of Alzheimer's disease are also provided.
    Type: Application
    Filed: September 26, 2018
    Publication date: April 25, 2019
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Patent number: 10112991
    Abstract: Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide are provided. Methods of using antibodies specific to the protofibrillar form of the beta-amyloid peptide in the field of Alzheimer's disease are also provided.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: October 30, 2018
    Assignee: SANOFI
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Publication number: 20180222967
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Application
    Filed: December 18, 2017
    Publication date: August 9, 2018
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • Publication number: 20180155450
    Abstract: The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.
    Type: Application
    Filed: December 8, 2017
    Publication date: June 7, 2018
    Inventors: Nicolas Baurin, Christian Beil, Carsten Corvey, Christian Lange, Danxi Li, Vincent Mikol, Anke Steinmetz, Ercole Rao
  • Publication number: 20180155444
    Abstract: The invention provides antibodies that specifically bind to Plasminogen Activator Inhibitor type-1 (PAI-1). The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.
    Type: Application
    Filed: November 10, 2017
    Publication date: June 7, 2018
    Inventors: Alla Pritsker, Patrick Grailhe, Alexey Rak, Magali Mathieu, Christopher Ryan Morgan, Nicolas Baurin, Bruno Poirier, Cyril Daveu, Francis Duffieux, Han Li, Dorothea Kominos, Philip Janiak
  • Patent number: 9879079
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: January 30, 2018
    Assignee: SANOFI
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • Patent number: 9845363
    Abstract: The invention provides antibodies that specifically bind to Plasminogen Activator Inhibitor type-1 (PAI-1), The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: December 19, 2017
    Assignee: Sanofi
    Inventors: Alla Pritsker, Patrick Grailhe, Alexey Rak, Magali Mathieu, Christopher Ryan Morgan, Nicolas Baurin, Bruno Poirier, Cyril Daveu, Francis Duffieux, Han Li, Dorothea Kominos, Philip Janiak
  • Publication number: 20160368977
    Abstract: The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of Alzheimer's disease.
    Type: Application
    Filed: June 2, 2016
    Publication date: December 22, 2016
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Publication number: 20160368976
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kanidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kanidin activity or detect Kallidin or des-Arg10-Kanidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Application
    Filed: May 25, 2016
    Publication date: December 22, 2016
    Applicant: Sanofi
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • Patent number: 9441040
    Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: September 13, 2016
    Assignee: Sanofi
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Carsten Corvey, Tarik Dabdoubi, Christian Engel, Peter Florian, Ingo Focken, Katja Kroll, Jochen Kruip, Christian Lange, Thomas Langer, Martin Lorenz, Vincent Mikol, Ercole Rao, Peter Wonerow
  • Publication number: 20160200831
    Abstract: The invention provides antibodies that specifically bind to Plasminogen Activator Inhibitor type-1 (PAI-1), The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.
    Type: Application
    Filed: August 13, 2014
    Publication date: July 14, 2016
    Inventors: Alla Pritsker, Patrick Grailhe, Alexey Rak, Magali Mathieu, Christopher Ryan Morgan, Nicolas Baurin, Bruno Poirer, Cyril Daveu, Francis Duffieux, Han Li, Dorothea Kominos, Philip Janiak
  • Publication number: 20160200811
    Abstract: The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.
    Type: Application
    Filed: November 20, 2015
    Publication date: July 14, 2016
    Inventors: Nicolas Baurin, Christian Beil, Carsten Corvey, Christian Lange, Danxi Li, Vincent Mikol, Anke Steinmetz, Ercole Rao
  • Patent number: 9382312
    Abstract: The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of Alzheimer's disease.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: July 5, 2016
    Assignee: Sanofi
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Patent number: 9376494
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 28, 2016
    Assignee: Sanofi
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • Publication number: 20160176970
    Abstract: The present invention relates to a peptide or peptide complex binding to ?2 integrin, to one or more nucleic acid(s) coding for the peptide or peptide complex, a recombinant cell producing the peptide or peptide complex, a method for producing the peptide or peptide complex, a pharmaceutical composition comprising the peptide or peptide complex or the nucleic acid(s) for use as a medicament, a method for detecting ?2 integrin and a screening method.
    Type: Application
    Filed: November 25, 2015
    Publication date: June 23, 2016
    Inventors: Carsten Corvey, Horst Blum, Béatrice Cameron, Tarik Dabdoubi, Stephanie Decary, Nicolas Baurin, David Papin, Christian Lange
  • Patent number: 9234039
    Abstract: The present invention relates to a peptide or peptide complex binding to ?2 integrin, to one or more nucleic acid(s) coding for the peptide or peptide complex, a recombinant cell producing the peptide or peptide complex, a method for producing the peptide or peptide complex, a pharmaceutical composition comprising the peptide or peptide complex or the nucleic acid(s) for use as a medicament, a method for detecting ?2 integrin and a screening method.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: January 12, 2016
    Assignee: SANOFI
    Inventors: Carsten Corvey, Horst Blum, Béatrice Cameron, Tarik Dabdoubi, Stephanie Decary, Nicolas Baurin, David Papin, Christian Lange